Dr. Damiano La Zara is a Senior Scientist in Oral Delivery Technologies at Novo Nordisk working on developing the next generation of oral therapeutic peptide and protein solid dosage forms. He received his PhD in Chemical Engineering at Delft University of Technology in collaboration with AstraZeneca focusing on controlled pulmonary delivery of inhaled drugs engineered with nanoscale films via atomic layer deposition. After his PhD, he worked as a Scientist at Johnson & Johnson in the Novel Oral Modalities team within Oral Solids Development, where he contributed to develop novel formulation concepts for oral delivery of macromolecules as well as supported the clinical development of the oral peptide JNJ-2113, which is advancing into Phase 3.